Roche files for approval to market hepatitis C treatment to HIV patients
September 08 2004 12:00 AM ET
Pharmaceutical giant Roche on Thursday announced that it has filed an application with the Food and Drug Administration to market a combination hepatitis C treatment to patients also infected with HIV. The company has already received approval to market its anti-hepatitis C drugs Pegasys and Copegus as a combination therapy for HIV-negative adults, but Roche is seeking the new approval to met an "unmet medical need," according to company officials. About 300,000 HIV-positive Americans also are infected with HCV, according to Roche, and a recent study by the company showed Pegasys-Copegus treatment reduced hepatitis C viral loads to undetectable levels in 40% of HIV patients treated with the drugs. Only 12% of HIV-HCV coinfected patients taking only Copegus and an older form of the drug interferon achieved undetectable HCV viral levels. The FDA granted fast-track status for the new application; a decision will be issued by next March.
- Girl Scouts Return $100K When Donor Demands It 'Not Be Used' For Trans Girls
- Tennessee Hardware Store Puts Up 'No Gays Allowed' Sign
- Girl Scouts Raise $100,000 in One Day After Dropping Transphobic Donor
- WATCH: Jon Stewart on GOP Reaction to Marriage Equality: 'Voldemort Has Risen'
- Op-ed: Why, No Matter What, I Still Can't Marry My Girlfriend
- The Top 175 Essential Films of All Time for LGBT Viewers